According to Zacks, “VCA Inc. is a national animal healthcare company operating primarily in the United States and Canada. It owns, operates and manages veterinary hospitals and veterinary-exclusive clinical laboratories in the country, supplies diagnostic imaging equipment and other medical technology products and related services to the veterinary industry, and provides various communication, professional education and marketing solutions to the veterinary community. VCA Inc., formerly known as VCA Antech, Inc., is headquartered in Los Angeles, California. “
Several other analysts have also issued reports on WOOF. Jefferies Group initiated coverage on shares of VCA in a research note on Wednesday, June 8th. They issued a hold rating for the company. Bank of America Corp. reiterated a buy rating on shares of VCA in a research note on Thursday, September 29th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. VCA presently has an average rating of Buy and a consensus target price of $71.00.
Shares of VCA (NASDAQ:WOOF) opened at 69.33 on Friday. The firm has a 50-day moving average of $70.10 and a 200 day moving average of $66.16. The firm has a market cap of $5.61 billion, a PE ratio of 24.73 and a beta of 1.23. VCA has a 52 week low of $44.00 and a 52 week high of $73.69.
VCA (NASDAQ:WOOF) last released its quarterly earnings data on Wednesday, July 27th. The company reported $0.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.05. VCA had a net margin of 9.93% and a return on equity of 16.86%. The firm had revenue of $653.50 million for the quarter, compared to the consensus estimate of $637.18 million. During the same quarter in the prior year, the company posted $0.70 earnings per share. The business’s revenue was up 19.1% on a year-over-year basis. Equities research analysts predict that VCA will post $2.93 EPS for the current fiscal year.
In related news, Director John B. Chickering, Jr. sold 2,302 shares of the stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $70.85, for a total transaction of $163,096.70. Following the completion of the transaction, the director now owns 10,992 shares in the company, valued at $778,783.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, COO Arthur J. Antin sold 34,000 shares of the stock in a transaction dated Friday, September 16th. The shares were sold at an average price of $69.03, for a total transaction of $2,347,020.00. Following the transaction, the chief operating officer now owns 89,691 shares of the company’s stock, valued at approximately $6,191,369.73. The disclosure for this sale can be found here. Corporate insiders own 4.60% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Acrospire Investment Management LLC bought a new position in VCA during the first quarter valued at $104,000. Walleye Trading LLC increased its stake in VCA by 312.0% in the second quarter. Walleye Trading LLC now owns 2,052 shares of the company’s stock valued at $139,000 after buying an additional 1,554 shares during the period. Creative Planning increased its stake in VCA by 43.5% in the second quarter. Creative Planning now owns 2,554 shares of the company’s stock valued at $173,000 after buying an additional 774 shares during the period. Bessemer Group Inc. increased its stake in VCA by 58.1% in the second quarter. Bessemer Group Inc. now owns 3,004 shares of the company’s stock valued at $203,000 after buying an additional 1,104 shares during the period. Finally, Wedbush Securities Inc. acquired a new stake in VCA during the second quarter valued at approximately $208,000. Institutional investors own 91.17% of the company’s stock.
VCA Company Profile
VCA Inc is an animal healthcare company. The Company operates through five segments. Its Animal Hospital segment provides veterinary services for companion animals and sells related retail and pharmaceutical products. Its Laboratory segment provides diagnostic laboratory testing services for veterinarians, both associated with its animal hospitals and those independent of the Company.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VCA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VCA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.